accacc2022acc2023acc2024acuteaddressingadjuvantadvancedahaamonganalysisartarterialasco2021ashash2021ash2023ash2024asthmaatrialbasedbccbenefitbenefitsbetabetterbloodbreakingbreastcancercarcinomacardiovascularcarecellcervicalchallengeschemotherapychest2024cholesterolchronicclinicalcombinationcontrolcontroversiescopdcoronarycovidcurrentdailydatadiabetesdiagnosisdiseasediseasesdoseearlyeaseasd2022effectefficacyehaeha2025ehra2022ersers2024escesc2021esc2022esc2023esc2024eshesh2022esh2023esh2024esh2025esmoesmo2021esmo2023esmo2024eular2024eventsevidencefactorsfailurefibrillationfirstfocusfocusedfuturegallenglpguidelineguidelineshealthhearther2hfpefhighhighlightshrhypertensionimmuneimmunotherapyimportanceimproveimprovesinfluenzainhibitorinhibitorsinsightsinterstitialinterviewisth2022jointkeynotekidneylandscapelargelateldlleukemialifelipidlongloweringlunglymphomamanagementmelanomametastaticmultiplemyeloidmyelomanavigatingnextnovelnoveltiesobesityoncologyoptimaloptionsoutcomesoverallpacingpatientpatientspembrolizumabpeoplephaseplacebopluspositivepostpracticepressurepreventionprimaryprogressionprostatepulmonaryrandomizedrealreceptorrelatedrenalrespiratoryresultsriskrolesabcs2024screeningsemaglutideseveresglt2showssitcstandardstatestudysurvivalsymposiumsyndromestargettargetedtermtherapeutictherapiestherapytreattreatmenttrialtrialsupdateupdatesvaccinationvaccineversuswcclworldwvcdc